Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/anti-angiogenic-strategies-in-breast-cancer-an-update-O584QewU8M
References (64)
-
B. Schneider, Molin Wang, M. Radovich, G. Sledge, S. Badve, A. Thor, D. Flockhart, B. Hancock, N. Davidson, J. Gralow, M. Dickler, E. Perez, M. Cobleigh, T. Shenkier, S. Edgerton, K. Miller (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 28
-
G. Bocci, K. Nicolaou, R. Kerbel (2002)
Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.Cancer research, 62 23
-
S. Dellapasqua, F. Bertolini, V. Bagnardi, E. Campagnoli, E. Scarano, R. Torrisi, Y. Shaked, P. Mancuso, A. Goldhirsch, A. Rocca, E. Pietri, M. Colleoni (2008)
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 30
-
L Gianni, F Cardoso, G Mariani (2007)
Exploratory evaluation of a sequential administration of docetaxel and sunitinib in women with advanced breast cancerBreast Cancer Res Treat, 106
-
T. Browder, C. Butterfield, B. Kräling, B. Shi, B. Marshall, M. O’Reilly, J. Folkman (2000)
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.Cancer research, 60 7
-
R. Torrisi, Vincenzo Bagnardi, Vincenzo Bagnardi, A. Cardillo, Francesco Bertolini, E. Scarano, L. Orlando, P. Mancuso, Alberto Luini, A. Calleri, G. Viale, G. Viale, A. Goldhirsch, M. Colleoni (2008)
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activityBritish Journal of Cancer, 99
-
J. Baselga, H. Roché, F. Costa, J. Segalla, H. Pinczowski, E. Ciruelos, S. Filho, P. Gómez, B. Eyll (2009)
SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo When Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer (BC).Cancer Research, 69
-
L. Lerner-Geva, L. Keinan-Boker, T. Blumstein, V. Boyko, L. Olmar, S. Mashiach, S. Mashiach, Jaron Rabinovici, Jaron Rabinovici, Gad Potashnik, E. Lunenfeld, J. Schenker, A. Shushan, Ami Fishman, Ilan Cohen, I. Vagman, Bruno Lunenfeld (2006)
Infertility, Ovulation Induction Treatments and the Incidence of Breast Cancer—a Historical Prospective Cohort of Israeli WomenBreast Cancer Research and Treatment, 100
-
C. Barrios, M. Liu, S. Lee, L. Vanlemmens, J. Ferrero, T. Tabei, X. Pivot, H. Iwata, K. Aogi, Marla Brickman, K. Zhang, K. Kern, Miguel Martín (2009)
Phase III Randomized Trial of Sunitinib (SU) vs. Capecitabine (C) in Patients (Pts) with Previously Treated HER2-Negative Advanced Breast Cancer (ABC).Cancer Research, 69
-
J. Baselga, J. Segalla, H. Roché, A. Giglio, E. Ciruelos, S. Filho, P. Gómez, A. Lluch, A. Llombart, F. Costa (2009)
3LBA SOLTI-0701: A double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared to placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC)Ejc Supplements, 7
-
Gagliardi Ar, B. Hennig, Collins Dc (1996)
Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors.Anticancer research, 16 3A
-
N. Steeghs, H. Gelderblom, J. Roodt, O. Christensen, P. Rajagopalan, M. Hovens, H. Putter, T. Rabelink, E. Koning (2008)
Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis InhibitorClinical Cancer Research, 14
-
B. Schneider, K. Miller (2005)
Angiogenesis of breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 8
-
A. Calleri, Anna Bono, V. Bagnardi, J. Quarna, P. Mancuso, C. Rabascio, S. Dellapasqua, E. Campagnoli, Y. Shaked, A. Goldhirsch, M. Colleoni, F. Bertolini (2009)
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus BevacizumabClinical Cancer Research, 15
-
Susana Banerjee, M. Dowsett, A. Ashworth, L. Martin (2007)
Mechanisms of Disease: angiogenesis and the management of breast cancerNature Clinical Practice Oncology, 4
-
N. Weidner, J. Semple, W. Welch, J. Folkman (1991)
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma.The New England journal of medicine, 324 1
-
E. Mayer, S. Isakoff, K. Hannagan, J. Savoie, J. Beckman, G. Klement, R. Gelman, E. Winer, H. Burstein (2009)
A phase I study of vandetanib and metronomic chemotherapy in advanced breast cancer.Cancer Research, 69
-
S. Taylor, S. Chia, S. Dent, M. Clemons, P. Grenci, L. Wang, A. Oza, P. Ivy, K. Pritchard, N. Leighl (2016)
A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
F. Perrone, C. Gallo, E. Rossi, A. Matteis (2010)
Reply to P.E. Lønning et alJournal of Clinical Oncology, 28
-
H. Verheul, H. Pinedo (2007)
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibitionNature Reviews Cancer, 7
-
H. Burstein, A. Elias, H. Rugo, M. Cobleigh, A. Wolff, P. Eisenberg, M. Lehman, B. Adams, C. Bello, S. Deprimo, C. Baum, K. Miller (2008)
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 11
-
P. Martin, George Counts, F. Appelbaum, Stephanie Lee, J. Sanders, H. Deeg, M. Flowers, K. Syrjala, J. Hansen, R. Storb, B. Storer (2010)
Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 6
-
T. Traina, H. Rugo, J. Caravelli, S. Patil, B. Yeh, M. Melisko, John Park, S. Geneus, Matthew Paulson, J. Grothusen, A. Seidman, M. Fornier, D. Lake, C. Dang, M. Robson, M. Theodoulou, C. Flombaum, L. Norton, C. Hudis, M. Dickler (2010)
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 4
-
E. Mayer, A. Nohria, K. Miller, H. Rugo, L. Carey, N. Ryabin, R. Gelman, E. Winer, H. Burstein (2010)
Cardiovascular safety of adjuvant bevacizumab for breast cancer.Journal of Clinical Oncology, 28
-
Zhi-Hua Zhu, Bing-Yu Sun, Yun-Zi Ma, J. Shao, H. Long, Xu Zhang, J. Fu, Lan-Jun Zhang, Xiaodong Su, Qiu-liang Wu, Peng Ling, Ming Chen, Ze-ming Xie, Y. Hu, T. Rong (2009)
Three immunomarker support vector machines-based prognostic classifiers for stage IB non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 7
-
F. Ademuyiwa, K. Miller (2008)
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.Clinical breast cancer, 8 Suppl 4
-
Xianfeng Wen, Guang Yang, Weiqun Mao, Angela Thornton, Jinsong Liu, R. Bast, X. Le (2006)
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapyOncogene, 25
-
N. Ferrara, H. Gerber, J. Lecouter (2003)
The biology of VEGF and its receptorsNature Medicine, 9
-
W. Gradishar, V. Kaklamani, T. Sahoo, D. Lokanatha, V. Raina, S. Bondarde, M. Jain (2009)
A Double-Blind, Randomized, Placebo-Controlled, Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib (SOR) in Combination with Paclitaxel (PAC) as a First-Line Therapy in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (BC).Cancer Research, 69
-
M. Langenberg, C. Herpen, J. Bono, J. Schellens, C. Unger, K. Hoekman, H. Blum, W. Fiedler, J. Drevs, F. Maulf, A. Fielding, J. Robertson, E. Voest (2009)
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 36
-
M Pegram, D Chan, RA Cichmann (2006)
Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor (VEGF) using trastuzumab and bevacizumab as first-line treatment of HER2-amplified breast cancerBreast Cancer Res Treat, 100
-
D. Slamon, H. Gómez, F. Kabbinavar, O. Amit, M. Richie, L. Pandite, V. Goodman (2008)
Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancerJournal of Clinical Oncology, 26
-
V. Diéras, J. Glaspy, A. Brufsky, I. Bondarenko, O. Lipatov, E. Perez, S. Chan, X. Zhou, S. Phan, N. Robert (2009)
5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)Ejc Supplements, 7
-
J. O’Shaughnessy, D. Miles, R. Gray, V. Diéras, E. Perez, R. Zon, J. Cortes, X. Zhou, S. Phan, K. Miller (2010)
A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC).Journal of Clinical Oncology, 28
-
A. Adenis, A. Mailliez, J. Rigot, L. Gamelin, M. Vanhuyse, E. Gamelin (2008)
Recurrent priapism related to oxaliplatin infusion.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 6
-
K. Miller, Molin Wang, J. Gralow, M. Dickler, M. Cobleigh, E. Perez, T. Shenkier, D. Cella, N. Davidson (2007)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.The New England journal of medicine, 357 26
-
I. Grills (2010)
Reply to S. Jiwnani et alJournal of Clinical Oncology, 28
-
J. Baar, P. Silverman, J. Lyons, P. Fu, F. Abdul-Karim, N. Ziats, J. Wasman, P. Hartman, J. Jesberger, L. Dumadag, Erin Hohler, R. Leeming, R. Shenk, Helen Chen, K. McCrae, A. Dowlati, S. Remick, B. Overmoyer (2009)
A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic BiomarkersClinical Cancer Research, 15
-
K. Kim, Bing Li, J. Winer, M. Armanini, N. Gillett, H. Phillips, N. Ferrara (1993)
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 362
-
E. Mayer, J. Ligibel, H. Burstein, K. Miller, L. Carey, H. Rugo, N. Ryabin, R. Gelman, E. Winer, A. Wolff (2010)
TBCRC 012: ABCDE, a phase II randomized study of adjuvant bevacizumab, metronomic chemotherapy (CM), diet and exercise after preoperative chemotherapy for breast cancer.Journal of Clinical Oncology, 28
-
Aliki Taylor, C. Frobisher, D. Ellison, R. Reulen, D. Winter, R. Taylor, C. Stiller, E. Lancashire, E. Tudor, C. Baggott, Shaun May, M. Hawkins (2009)
Survival after second primary neoplasms of the brain or spinal cord in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 34
-
K. Miller, J. Trigo, C. Wheeler, A. Barge, J. Rowbottom, G. Sledge, J. Baselga (2005)
A Multicenter Phase II Trial of ZD6474, a Vascular Endothelial Growth Factor Receptor-2 and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Previously Treated Metastatic Breast CancerClinical Cancer Research, 11
-
Jean-Mare Guinebretière, G. Monique, André Gavoille, Jaqueline Bahi, G. Contesso (1994)
Angiogenesis and risk of breast cancer in women with fibrocystic disease.Journal of the National Cancer Institute, 86 8
-
A. Bottini, D. Generali, M. Brizzi, S. Fox, A. Bersiga, S. Bonardi, G. Allevi, S. Aguggini, G. Bodini, M. Milani, R. Dionisio, C. Bernardi, Arianna Montruccoli, P. Bruzzi, A. Harris, L. Dogliotti, A. Berruti (2006)
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 22
-
A. Brufsky, I. Bondarenko, V. Smirnov, S. Hurvitz, E. Perez, O. Ponomarova, I. Vynnychenko, R. Swamy, H. Mu, R. Rivera (2009)
RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer.Cancer Research, 69
-
M. Skobe, P. Rockwell, N. Goldstein, Silvia Vosseler, N. Fusenig (1997)
Halting angiogenesis suppresses carcinoma cell invasionNature Medicine, 3
-
K. Miller, L. Chap, F. Holmes, M. Cobleigh, P. Marcom, L. Fehrenbacher, M. Dickler, B. Overmoyer, J. Reimann, A. Sing, V. Langmuir, H. Rugo (2005)
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 4
-
N. Robert, V. Diéras, J. Glaspy, A. Brufsky, I. Bondarenko, O. Lipatov, E. Perez, D. Yardley, S. Chan, Xian Zhou, S. Phan, J. O’Shaughnessy (2011)
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 10
-
AJ Beer, M Niemeyer, J Carlsen (2008)
Patterns of alphavbeta3 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PETJ Nucl Med, 49
-
J. Bergh, R. Greil, N. Voytko, A. Makhson, J. Cortés, A. Lortholary, X. Huang, C. Giorgetti, K. Kern, M. Lichinitser (2010)
Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
-
M. Rubin, J. Barton, D. Shipley, E. Arrowsmith, N. Peacock, L. Hart, J. Evans, E. Vásquez, H. Burris, D. Yardley (2016)
Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
E Mayer, S Hamel, J Savoie (2007)
AZD2171 for refractory breast cancer: a phase 2 trialBreast Cancer Res Treat, 106
-
H Burstein, D Spigel, K Kindsvogel (2005)
Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II studyBreast Cancer Res Treat, 94
-
D. Miles, A. Chan, G. Romieu, L. Dirix, J. Cortés, X. Pivot, P. Tomczak, T. Taran, N. Harbeck, G. Steger (2008)
Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.Journal of Clinical Oncology, 26
-
G. Mariani, F. Cardoso, T. besse-Hammer, L. Viganò, A. Liljegren, L. Verkh, Xin Huang, C. Giorgetti, J. Bergh, L. Gianni (2008)
Sequential administration of sunitinib (SU) and docetaxel (D) in women with advanced breast cancer (ABC): an exploratory evaluationJournal of Clinical Oncology, 26
-
E. Mayer, S. Dhakil, T. Patel, S. Sundaram, C. Fabian, M. Kozloff, R. Qamar, F. Volterra, H. Parmar, M. Samant, H. Burstein (2010)
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.Annals of oncology : official journal of the European Society for Medical Oncology, 21 12
-
A. Moreno-Aspitia, R. Morton, D. Hillman, W. Lingle, K. Rowland, M. Wiesenfeld, P. Flynn, T. Fitch, E. Perez (2009)
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 1
-
G. Bianchi, S. Loibl, C. Zamagni, S. Salvagni, Guenter Raab, S. Siena, N. Laferriere, C. Peña, C. Lathia, L. Bergamini, L. Gianni (2009)
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancerAnti-Cancer Drugs, 20
-
S. Ivy, J. Wick, Bennett Kaufman (2009)
An overview of small-molecule inhibitors of VEGFR signalingNature Reviews Clinical Oncology, 6
-
M. Kozloff, E. Chuang, A. Starr, P. Gowland, P. Cataruozolo, M. Collier, L. Verkh, X. Huang, K. Kern, K. Miller (2009)
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancerAnnals of Oncology, 21
-
N. Robert, V. Diéras, J. Glaspy, A. Brufsky, I. Bondarenko, O. Lipatov, E. Perez, D. Yardley, X. Zhou, S. Phan (2009)
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 15_suppl
-
J. Crown, V. Diéras, E. Starosławska, D. Yardley, N. Davidson, T. Bachelot, V. Tassell, X. Huang, K. Kern, G. Romieu (2010)
Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 18_suppl
-
S. Goldfarb, M. Dickler (2009)
Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: Clinical and biological activity: Torrisi R, Bagnardi V, Cardillo A, et al (European Inst of Oncology Milan, Italy; et al) Br J Cancer 99:1564-1571, 2008§Breast Diseases: A Year Book Quarterly, 20
-
A. Beer, M. Niemeyer, J. Carlsen, M. Sarbia, J. Nährig, P. Watzlowik, H. Wester, N. Harbeck, M. Schwaiger (2008)
Patterns of αvβ3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PETJournal of Nuclear Medicine, 49
- Publisher
- Springer Journals
- Copyright
- Copyright © 2010 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Surgical Oncology; Internal Medicine; Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-010-0023-3
- Publisher site
- See Article on Publisher Site
Abstract
Angiogenesis plays a role in primary tumor growth and metastatic potential of breast cancer, and within the past decade, the development of angiogenesis inhibitors has been a significant focus of clinical research efforts. Multiple studies to date have confirmed a role for bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), in combination with chemotherapy in the treatment of metastatic breast cancer. Efforts to determine the efficacy of second-generation VEGF receptor antagonists in breast cancer patients are ongoing. In addition, trials are underway to investigate potential synergy between anti-angiogenic agents and other classes of breast cancer therapeutics and to examine the efficacy of angiogenesis inhibition in nonmetastatic disease. Preliminary work evaluating predictors of response to therapy, including serologic biomarkers, class-effect toxicity, or dynamic radiologic change, and pharmacogenetics, has been promising; however, future study is critical to best identify the patient population most likely to benefit from anti-angiogenic therapy.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Sep 24, 2010